References
- Jagannath S., Vesole D.H., Glenn L., et al. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80: 1666–72
- Dimopoulos M., Alexanian R., Przepiorka D., et al. Thiotepa, busulfan, and cyclophosphmide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993; 82: 2324–28
- Ling V., Thompson L.H. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J. Cell, Physiol. 1974; 83: 103–16
- Dalton W.S., Grogan T.M., Dune B.G.M., et al. Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of PGP and potential circumvention by addition of verapamil to chemotherapy. J. Clin, Oncol. 1989; 7: 415–424
- Nooter K., Sonneveld P. Clinical relevance of P-glycoprotein expression in haematological malignancies. Leukemia Res. 1994; 18: 233–43
- Salmon S.E., Dalton W.S., Grogan T.M., et al. Multidrug resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood. 1991; 78: 44–50
- Sonneveld P., Durie B.G.M., Lockhutst H.M., et al. Modulation of multidrug resistant myeloma by cyclosporine. Lancer 1992; 340: 255–59
- Durie B.G.M., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features. response to treatment and survival. Cancer 1975; 36: 842–854
- Dimopoulos M., Barlogie B., Smith T., Alexanian R. High Serum lactate dehydrogenase levels as a marker for drug resistance and short survival in multiple myeloma. Ann. Int. Med. 1991; 115: 931–35
- Barlogie B., Alexanian R., Smith L., et al. Prognostic implications of tumor cell DNA and RN A content in multiple myeloma. Blood 1985; 66: 338–341
- Weber D.M., Dimopoulos M.A., Alexanian R. Increased neurotoxicity with VAD-cyclosporine in multiple myeloma (letter). Lancet 1993; 4: 558–59
- Grogan T., Dalton W., Rybski J., et al. Optimization of immuno-cytochemical P-glycoprotein assessment in multidrug resistant plasma cell myeloma using three antibodies. Lab. Invest. 1990; 63: 315–824
- Dimopoulos M.A., Weber D.M., Hester J., et al. Intensive sequential therapy for VAD-resistant multiple myeloma. Leutkemia and Lymphoma. 1994; 13: 479–84
- Grogan T., Spier C., Salmon S., et al. P-glycopmtein expression in human plasma cell myeloma; correlation with prior chemotherapy. Blood. 1993; 81: 190–95
- Cornelissen J.J., Sonneveld P., Schoester P., et al. MDR-1 expression and response to vincristine. doxorubicin, and dexamethusone chemotherapy in multiple myeloma refractory to alkylating agents. J. Clin, Oncol. 1994; 1: 115–119
- Barlogie B., Jagannath S., Dixon D., et al. High dose melphalan and granulocyte-macrophage colony stimulating factors for refractory multiple myeloma. Blood. 1990; 76: 677–80
- Ross D.D., Wooten P.J., Sridhara R., et al. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood. 1993; 82: 1288–99
- Sonneveld P., Schoester M., De Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J. Clin, Oncol. 1994; 12: 1584–91
- Thiebaut F., Tsurvo E., Hamada H., et al. Cellular localization of the multidrug resistance gene product p-glycoprotein in normal human tissues. Proc, Natl. Acad, Sci. USA 1987; 84: 7735–7738
- Bartlett N.L., Fisher G.A., Halsey J., et al. A phase I trial of doxorubicin (D) with cyclosporine (CSA) as a modulator of multidrug resistance (MDR). Proceedings of ASCO 1993; 12: 142, Abst#366
- Lum Kaubisch B.L.S., Yahanda A.M., et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J. Clin. Oncol. 1992; 10: 1635–32
- Jonsson B., Nilsson K., Nygren P., et al. SDZ PSC-833—a novel potent in vitro chemosensitizer in multiple myeloma. Anti-Cancer Drugs. 1992; 3: 611–646